Aryl amide small-molecule inhibitors of microRNA miR-21 function
作者:Yuta Naro、Meryl Thomas、Matthew D. Stephens、Colleen M. Connelly、Alexander Deiters
DOI:10.1016/j.bmcl.2015.07.016
日期:2015.11
MicroRNAs (miRNAs) are single stranded RNA molecules of similar to 22 nucleotides that negatively regulate gene expression. MiRNAs are involved in fundamental cellular processes, such as development, differentiation, proliferation, and survival. MiRNA misregulation has been linked to various human diseases, most notably cancer. MicroRNA-21 (miR-21), a well-established oncomiR, is significantly overexpressed in many types of human cancers, thus rendering miR-21 a potential therapeutic target. Using a luciferase-based reporter assay under the control of miR-21 expression, a high-throughput screen of >300,000 compounds led to the discovery of a new aryl amide class of small-molecule miR-21 inhibitors. Structure-activity relationship (SAR) studies resulted in the development of four aryl amide derivatives as potent and selective miR-21 inhibitors. The intracellular levels of various miRNAs in HeLa cells were analyzed by qRT-PCR revealing specificity for miR-21 inhibition over other miRNAs. Additionally, preliminary mechanism of action studies propose a different mode of action compared to previously reported miR-21 inhibitors, thus affording a new chemical probe for future studies. (C) 2015 Elsevier Ltd. All rights reserved.
METHOD FOR STORING QUATERNARY AMMONIUM SALT
申请人:TOKUYAMA CORPORATION
公开号:EP1178043B1
公开(公告)日:2005-12-28
HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR
申请人:Pharmaxis Ltd.
公开号:EP2222160A2
公开(公告)日:2010-09-01
PROGRANULIN MODULATORS AND METHODS OF USING THE SAME
申请人:Arkuda Therapeutics
公开号:EP3983401A1
公开(公告)日:2022-04-20
[EN] HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR<br/>[FR] INHIBITEURS DE SSAO/VAP-1 DE TYPE HALOALLYLAMINES ET LEURS UTILISATIONS
申请人:PHARMAXIS LTD
公开号:WO2009066152A2
公开(公告)日:2009-05-28
The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.